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INTRODUCTION
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable, potentially life-threatening complication associated with conditioning regimens for hematopoietic stem cell transplantation (HSCT), including reduced-intensity regimens. [1] [2] [3] [4] VOD/SOS also can occur as a complication of chemotherapy alone. [5] [6] [7] [8] [9] The reported mean incidence of VOD/SOS following HSCT is 13.7% (range, 0-62.3%). 3 Even among patients undergoing reduced-intensity conditioning for allogeneic HSCT, an incidence of 8.8% has been reported. 4 Following HSCT, VOD/SOS with concomitant multi-organ dysfunction (MOD) has an associated mortality rate that may exceed 80%. 3 The incidence and mortality rate of VOD/SOS following nontransplant-associated chemotherapy are not known. A number of agents have been reported to be associated with an increased risk of VOD/SOS in the non-HSCT setting, including inotuzumab and gemtuzumab ozogamicin, 8, 9 vincristine, and/or actinomycin D. [10] [11] [12] [13] In the context of HSCT, the primary event in the pathogenesis of VOD/SOS is injury to hepatic sinusoidal endothelial cells and hepatocytes, usually within the first 21 days post-HSCT, resulting in a prothrombotic-hypofibrinolytic state and sinusoid obstruction. 14 Clin- ically, VOD/SOS is typically characterized by hepatomegaly, hyperbilirubinemia, jaundice, ascites, and weight gain. 1, [15] [16] [17] [18] Hepatocellular necrosis and vascular occlusion can lead to the hepatorenal syndrome, liver failure, MOD, and death. 1, 3, 15, 19 The pathophysiology in the non-HSCT setting has not been well described, but is presumed to be similar.
In the United States, defibrotide is approved for the treatment of hepatic VOD/SOS post HSCT in patients with renal or pulmonary dysfunction, and in the European Union for the treatment of severe hepatic VOD/SOS following HSCT in adults, adolescents, children, and infants aged older than 1 month. 20, 21 A position statement published by the European Society for Blood and Marrow Transplantation recommends defibrotide for VOD/SOS treatment, 19 and guidelines from the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees state that defibrotide is the treatment of choice for VOD/SOS and "should be started as early as possible". 22 Defibrotide sodium is a polydisperse mixture of predominantly single-stranded polydeoxyribonucleotides derived from porcine mucosal DNA. Preclinical data suggest that defibrotide increases the expression of tissue plasminogen activator and thrombomodulin and decreases the expression of von Willebrand factor and plasminogen activator inhibitor-1 and reduces endothelial-cell activation, promoting the restoration of thrombotic-fibrinolytic balance and protecting the endothelial cells from the continued damage caused by chemotherapy and tumor necrosis factor-. 23 Completed clinical trials of defibrotide are usually restricted to patients with diagnosis of VOD/SOS following HSCT. In a phase 2 dose-finding trial that tested two dosage levels (25 mg/kg/day and 40 mg/kg/day) in a mixed adult and pediatric population with VOD/SOS and MOD following HSCT, the lower dose level was found to be the appropriate dosage for further study, because of similar efficacy and a safety profile that was more favorable. 24 A subsequent phase 3 trial in patients with VOD/SOS and MOD following HSCT reported significant improvement in survival at day +100 post-HSCT and in complete response (i.e., total bilirubin <2 mg/dl and resolution of MOD) among patients who received defibrotide 25 mg/kg/day, compared with historical controls who received standard of care alone. 25 In addition, defibrotide has demonstrated efficacy in VOD/SOS prevention in pediatric HSCT patients in a large phase 3 trial (12% of patients [n = 180] with defibrotide prophylaxis developed VOD/SOS by day +30 after HSCT vs. 20% [n = 176] in the control group) 26 and in adults and pediatric patients in a single-center study (0% of patients [n = 248] with defibrotide prophylaxis developed VOD/SOS at day +100 after HSCT vs. 4.8% [n = 248] in the control group). 27 Defibrotide was prospectively evaluated in an expanded-access treatment-investigational new drug (T-IND) study initiated in 2007 (ClinicalTrials.gov identifier NCT00628498). This was a multicenter, single-arm, open-label, US trial designed to provide defibrotide (25 mg/kg/day) to patients who developed hepatic VOD/SOS with or without MOD following HSCT or nontransplant-associated chemotherapy. 28 The results of the final analysis of this trial presented here focus on defibrotide usage, tolerability, and safety in patients whose VOD/SOS developed following nontransplant-associated chemotherapy.
METHODS

Study participants
In the original 2007 version of the protocol for the T-IND study, all patients were required to have a diagnosis of VOD/SOS by Baltimore criteria 16 or by biopsy by day +35, and to have MOD (renal and/or respiratory failure) by day +45 post HSCT. The Baltimore criteria call for a serum bilirubin level ≥2mg/ml, plus at least two of the following three findings: ascites (by radiographic or physical examination), weight gain ≥5% from the baseline value, and hepatomegaly. Renal dysfunction was defined by a tripled serum creatinine level, a creatinine clearance level, or glomerular filtration rate ≤40% of the baseline value, or dialysis dependence. Respiratory dysfunction was defined by need for oxygen supplementation, an oxygen saturation ≤90% on room air, or ventilator dependence.
The study protocol was amended in 2009 to also include patients with VOD/SOS following nontransplant-associated chemotherapy, without MOD, and (in a 2012 amendment) with VOD/SOS diagnosed by modified Seattle criteria, 15 which require two or more of: bilirubin ≥2 mg/dl, hepatomegaly or right upper quadrant pain, and weight gain (≥5% in this study). The requirement to have VOD/SOS diagnosed by day +35 was removed. Exclusion criteria included clinically significant, uncontrolled acute bleeding, medication that increases the risk of hemorrhage, need for more than one vasopressor, and pregnancy.
The post hoc analyses presented here pertain to the subset of enrolled patients who had received nontransplant-associated chemotherapy. Results for the HSCT population were reported previously. 28 
Study drug dosing
For all patients, the recommended defibrotide regimen was 25 mg/kg/day, administered as a 2-hour intravenous infusion of 6.25 mg/kg every 6 hr. 20 Dosing was based on each patient's weight prior to chemotherapy, with doses rounded to the nearest 10 mg for patients of any age >35 kg, and rounded to the nearest 5 mg for pediatric patients <35 kg. The recommended minimum treatment duration was 21 days. After 21 days, treatment was recommended to continue until resolution of symptoms of VOD/SOS (and MOD, if present) or the patient's discharge from the hospital. Blood parameters that were monitored and maintained during treatment were hemoglobin >8 mg/dl, platelet count >30,000/mm 3 , international normalized ratio <1.5 with fresh frozen plasma, and fibrinogen >150 mg/dl, with factor replacement as necessary. The protocol recommended that treatment was to be discontinued or withheld for clinically significant bleeding defined as either >15 cc/kg packed red blood cells/24 hr or bleeding from a potentially lifethreatening site (pulmonary hemorrhage or central nervous system bleeding) irrespective of amount of blood loss. The cause of bleeding was to be treated, and, after the patient was hemodynamically stable and bleeding had stopped, consideration was to be given to resuming treatment at the same dose and infusion volume. In the event of recurrent severe significant bleeding, defibrotide was to be permanently discontinued.
Efficacy analyses
The original T-IND program followed patients to day +100 after HSCT, and day +100 survival was the primary efficacy endpoint for the analysis, as this is a standard outcome milestone for HSCT studies of patients with VOD/SOS. When the protocol was amended to permit enrollment of patients with VOD/SOS after nontransplant-associated chemotherapy (August 2009), the data were collected for 100 days after the first dose of the most recent course of chemotherapy, and the efficacy endpoint of day +100 was not adjusted for these patients.
To obtain a population with a clinically meaningful follow-up time after defibrotide initiation for this post hoc analysis, only patients who initiated defibrotide within 30 days of starting chemotherapy were included in the primary efficacy assessment, and the efficacy endpoint for analysis was survival at day +70 following the start of defibrotide (i.e., for a total of up to 100 days after the start of chemotherapy). 
Safety measures
Safety was assessed by adverse events (AEs), as reported by the study's investigators. For this purpose, AEs were defined as any adverse event that began or worsened after a patient's first dose of defibrotide.
Symptoms of the disease targeted by a patient's chemotherapy were not to be reported as AEs unless the event was considered serious.
Based on the investigator's assessment, each AE was classified as to whether it was at least possibly related to defibrotide. Hemorrhagic events and hypotension were predefined as AEs of special interest. The study collected limited laboratory data, primarily to support VOD/SOS diagnosis and outcome assessment. Accordingly, these data were not employed for study drug safety evaluation.
Ethical conduct
The study protocol was approved by each institution's independent ethics committee or institutional review or privacy board and was conducted in accordance with the principles of the Declaration of Helsinki or with local laws and regulations. All patients or guardians, as appropriate, provided written informed consent and written Health Insurance Portability and Accountability Act authorization. 
RESULTS
Study participants
TA B L E 2
Survival at day +70 after defibrotide initiation among patients treated with defibrotide for VOD/SOS within 30 days of starting nontransplant-associated
Survival
Point estimate and Kaplan-Meier estimated survival at day +70 after defibrotide initiation for the 82 patients with VOD/SOS following nontransplant-associated chemotherapy are summarized in Table 2 .
At day +70 after defibrotide was started, the overall Kaplan-Meier 
Safety
Among the 82 patients with VOD/SOS following nontransplantassociated chemotherapy who initiated defibrotide treatment within 30 days of first chemotherapy dose, 54 patients (65.9%) reported one or more AE, including 33 patients (40.2% of 82) with AEs rated as serious and 22 patients (26.8% of 82) with AEs considered by the investigators to be at least possibly related to defibrotide ( Table 3 ). The most common serious AEs were new or worsening MOD (in seven patients; 8.5%), veno-occlusive liver disease, hypoxia, and respiratory failure (each in five patients; 6.1%), and pulmonary hemorrhage (in four patients; 4.9%), followed by febrile neutropenia, encephalopathy, renal failure, and hypotension (each in three patients; 3.7%) and hepatic failure and sepsis (each in two patients; 2.4%). The most common
AEs possibly related to defibrotide were mouth and pulmonary hemorrhage (each in three patients; 3.7%), followed by hematochezia, nausea, encephalopathy, epistaxis, and hypotension (each in two patients;
2.4%). Across all patients, one death (1.2%) from pulmonary hemorrhage and hypotension in a patient with MOD was considered to be related to defibrotide.
AEs by System Organ Class and Preferred Term consistent with hemorrhage were reported in 18 of 82 patients (22.0%). The events in more than one patient were pulmonary hemorrhage (in five patients;
6.1%), epistaxis and mouth hemorrhage (each in three patients; 3.7%), and hematochezia (in two patients; 2.4%). The organ systems most commonly affected in these events were the gastrointestinal and respiratory systems (each in nine patients; 11.0%). Hemorrhagic AEs were more common among patients with MOD (34.2%) than among patients without MOD (11.4%).
DISCUSSION
Most published studies of defibrotide for VOD/SOS have been restricted to post-HSCT patients. However, VOD/SOS can occur following nontransplant-associated chemotherapy. Here we report defibrotide usage, tolerability, and safety data that were collected from a post hoc analysis subgroup of T-IND patients whose VOD/SOS developed after chemotherapy alone. Of 1,154 patients in the T-IND, 137 (12%) patients had nontransplant-associated VOD/SOS. 28 Similarly, in the international defibrotide compassionate use program (CUP) 79/710 (11.1%) patients had nontransplant-associated VOD/SOS. 29 In another study of gemtuzumab and chemotherapy as first-line therapy for AML patients, 7/72 (10%) developed VOD/SOS. 30 As patients typically receive multi-agent chemotherapy, it is difficult to implicate specific drugs as causing VOD/SOS. Moreover, the incidence of VOD/SOS and survival outcomes associated with a specific agent or combinations of agents have not been routinely reported, and thus, are not known for this population of patients.
However, it is notable that individual reports in the literature have demonstrated risk of VOD/SOS associated with certain chemotherapy treatments. For example, the incidence of VOD/SOS in ALL patients treated with inotuzumab ozogamicin was shown to be significantly higher than in patients receiving standard chemotherapy (13% vs.
1%, respectively); however, these data included all VOD/SOS events within two years of randomization, the majority of which were after follow-up HSCT. 9 An increased risk for development of VOD/SOS, with or without HSCT, also has been recognized in patients with AML treated with gemtuzumab ozogamicin. 8 Thioguanine, vincristine, and high-dose actinomycin-D also have been reported to be associated with the development of VOD/SOS. [10] [11] [12] [31] [32] [33] The present analysis was not powered to investigate any possible associations with specific agents or regimens, and no inferences can be made from the results.
Although the design of the present study did not permit either a concomitant or historical control group, the analysis encompassed 82 patients with nontransplant-associated chemotherapy and suggests that defibrotide may be efficacious in VOD/SOS in this set- The AE profile observed in the present cohort was consistent with that seen in the VOD/SOS population in the post-HSCT setting, and with the known safety profile of defibrotide in such patients. 20, 23, 25 In the T-IND overall, defibrotide tolerability was better than in other VOD/SOS patient populations, 24, 25 prophylaxis study, 26 hemorrhage was the most commonly reported treatment-related AE; however, cumulative hemorrhage incidence was the same between the defibrotide group (22%) and the control group (21%). Also, thrombocytopenia and coagulopathy have been observed irrespective of defibrotide treatment, 25 which makes it difficult to attribute causality for these events. In the subgroup of nontransplantassociated chemotherapy patients with MOD in this study, 13 (34%) had a hemorrhagic AE, and 6 (16%) patients with MOD discontinued defibrotide due to a treatment-related AE, mostly hemorrhagic events.
Interpretation of the present analysis is limited by the source of the data, a study designed to provide access to therapy without randomization, which lacked an appropriate control group or formal onsite monitoring. On the other hand, the analysis provides a substantial dataset to support the feasibility of using defibrotide for treatment of patients with nontransplant-associated VOD/SOS, particularly in the larger group of pediatric patients. Because only 12.0% of patients in the T-IND study received treatment for nontransplant-associated VOD/SOS, it is unlikely that a sufficient number of patients could ever be accrued to a randomized controlled study of defibrotide versus best supportive care. Moreover, in the same way that ethical concern prevented withholding a potentially therapeutic modality with an acceptable safety profile from patients with VOD/SOS following HSCT, 25 ethical concern makes it highly unlikely that a randomized study of defibrotide versus best supportive care would ever be undertaken in a nontransplant population. Soiffer has served on advisory committees with Jazz Pharmaceuticals.
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